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Abstract
Background and aims: Fecal microbiota transplantation (FMT) has gained interest as a novel
treatment option for inflammatory bowel diseases (IBD). While publications describing FMT as
therapy for IBD have more than doubled since 2012, research that investigates FMT treatment
efficacy has been scarce. We conducted a systematic review and meta-analysis to evaluate the
efficacy of FMT as treatment for patients with IBD.
Methods: A systematic literature search was performed through May 2014. Inclusion criteria
required FMT as the primary therapeutic agent. Clinical remission (CR) and/or mucosal healing
were defined as primary outcomes. Studies were excluded if they did not report clinical
outcomes or included patients with infections.
Results: Eighteen studies (9 cohort studies, 8 case studies and 1 randomized controlled trial)
were included. 122 patients were described (79 ulcerative colitis (UC); 39 Crohn's disease (CD); 4
IBD unclassified). Overall, 45% (54/119) of patients achieved CR during follow-up. Among the
cohort studies, the pooled proportion of patients that achieved CR was 36.2% (95% CI 17.4%–
60.4%), with a moderate risk of heterogeneity (Cochran's Q, P = 0.011; I2 = 37%). Subgroup
analyses demonstrated a pooled estimate of clinical remission of 22% (95% CI 10.4%–40.8%) for
UC (P = 0.37; I2 = 0%) and 60.5% (95% CI 28.4%–85.6%) for CD (P = 0.05; I2 = 37%). Six studies
performed microbiota analysis.ta transplantation; CR, clinical remission; IBD, inflammatory bowel disease; CD, Crohn's disease; UC,
ficile infection; PICOS, Population, Intervention, Control, Outcomes, Study design; PRISMA, Preferred
ws and Meta-Analyses; ACG, American College of Gastroenterology; DDW, digestive disease week;
Crohn's and Colitis Organization; NASPGHAN, North American Society for Pediatric Gastroenterology,
uropean Society for Pediatric Gastroenterology, Hepatology and Nutrition.
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1570 R.J. Colman, D.T. RubinConclusions: This analysis suggests that FMT is a safe, but variably efficacious treatment for IBD.
More randomized controlled trials are needed and should investigate frequency of FMT
administration, donor selection and standardization of microbiome analysis.
© 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Fecal microbiota transplantation (FMT) has become an
increasingly popular avenue of inquiry for patients with
inflammatory bowel disease (IBD). Prior to 2013, research
that explored the treatment efficacy of FMT was generally
limited to patients with Clostridium difficile infections
(CDI). Data from this body of research demonstrated
excellent results within this patient population.1 FMT
research has been sparse outside of the context of CDI and
is limited to case reports alone for the IBD patient
population.2–9 As a result, the two systematic reviews of
this topic were completed in 2012 and 2013 and were
predominantly comprised of case reports.10,11 These studies
included IBD patients both with and without co-morbid CDI
and were limited in quantitative analysis due to the
statistical limitations of existing publications.
In this updated systematic review and meta-analysis, we
investigate the efficacy of FMT as therapy for IBD. We
performed a pooled analysis and meta-analysis with data
from the first published cohort studies on this topic. Second-
arily, we examined the safety of FMT among the IBD population
and treatment efficacy associated with microbiota analysis.2. Methods
2.1. Search strategy and study selection
A systematic literature search was performed and used
MOOSE, PRISMA and Cochrane guidelines.12–14 The MOOSE
checklist was followed accordingly.12,14 The systematic
literature search was conducted using EMBASE (1947–May
2014), MEDLINE (1950–May 2014), the Cochrane library and
Biomed Central Cases Database. Proceedings from annual
meetings of national and international gastroenterology
conferences (American College of Gastroenterology (ACG),
Digestive Disease Week (DDW), Advances in IBD (AIBD),
European Crohn's and Colitis Organization (ECCO), North
American Society for Pediatric Gastroenterology, Hepatology
and Nutrition (NASPGHAN), European Society for Pediatric
Gastroenterology, Hepatology and Nutrition (ESPGHAN) and
the British Society of Gastroenterology annual meeting) were
searched manually from 2010 up to and including May 2014.
A Population, Intervention, Comparison, Outcomes, Study
(PICOS) design question was designed to determine inclusion
and exclusion criteria. Databases were searched with the
following alternatives for fecal microbiota transplant: “fecal”,
1571Fecal Therapy for Inflammatory Bowel Disease“faecal”, “microbiota”, “microflora”, “feces”, “faeces”,
“stool”, “fecal flora”, and “faecal flora”; individually with
each of the following variations on transplant: “transplant”,
“transfusion”, “implantation”, “implant”, “instillation”, “mi-
crobiota”, “donor”, “enema”, “reconstitution”, “infusion”,
“therapy”, and “bacteriotherapy”, as earlier identified by
Anderson et al.10 These terms were searched alone and in
combination. The results were combined with varied IBD
descriptor terms (“Crohn disease”, “Crohn's disease”, “inflam-
matory bowel disease”, “colitis”, “ileitis”, “regional enteri-
tis”, “ulcerative colitis”, “IBD”, “CD”, or “UC”) and combined
by the Boolean term “AND”. This strategy was used both as
Medical Subject Headings (MeSH) terms if available and as free
text. Searching was limited to publications with human
subjects. No language limits were used.
Two authors independently reviewed all articles. Inclu-
sion criteria for publications required inclusion of IBD
patient sample and clearly described clinical treatment
outcomes. Studies were excluded if clinical endpoints were
not reported or if the study included only patients withTable 1 Newcastle–Ottawa Scale for assessing quality of cohort
Quality assessment
scale
Accepted
criteria
Vermeire
et al.
(2012)27
Kunde
et al.
(2012)23
Kump
et al.
(2013)22
Selection
Representativeness
of the exposed
cohort
Representative
of average
child/adult
with IBD
Sex, age and
disease severity
– * –
Ascertainment of
FMT exposure
Secure
records,
structured
interview
* * *
Demonstration that
outcome of
interest was not
present at start
of study
Evidence of no
prior FMT
exposure
– – *
Outcome
Assessment of
outcome
Utilization of
predefined
disease
activity scores
or mucosal
evaluation?
* * *
Follow-up enough
for outcome to
occur?
Follow-up for
at least
3 months
– – *
Adequacy of follow
up of cohorts
Follow-up of
complete co-
hort or unlikely
to introduce
bias?
* * *
Total (max = 6) 3 4 5
a 4/5 pts no prior FMT.co-morbid infections. Studies that included patients with
concomitant infections (e.g. CDI) were considered only if
there were clear descriptions of clinical outcomes and
patient characteristics of the remaining patients without
co-morbid infection.
Data was extracted using preset criteria into a Microsoft
Excel Office Professional Plus 2010 (Microsoft, Redmont,
WA) spread sheet. Study characteristics and outcomes were
reported and a separate spread sheet was used to record
individual patient characteristics and outcomes.2.2. Risk of bias
Quality and bias of cohort studies were assessed by an
adjusted version of the Newcastle–Ottawa Scale for cohort
studies.13 The scale was adjusted for use in cohort studies
without a control group (Table 1). The Newcastle–Ottawa
Scale is used to assess quality and biases of studies and
assigns points for specific biases on a nine-point scale. Thisstudies.
Angelberger
et al.
(2013)20
Suskind
et al.
(2013)25
Landy
et al.
(2013)24
Zhang
et al.
(2013)28
Damman
et al.
(2014)21
Vaughn
et al.
(2014)26
– * – – * *
* * * * * *
* a – – – * *
* * * * * *
* – – – * *
* * * * * *
5 4 3 3 6 6
1572 R.J. Colman, D.T. Rubinwas adjusted to a six-point scale after the questions that
assess for control groups were removed. The first 3 points
assessed for cohort selection and included representative-
ness of the IBD cohort (for age, sex and disease severity),
ascertainment of FMT exposure, and evidence that there
was no prior exposure to FMT. The remaining 3 points were
awarded for outcome quality (that utilized predefined
disease activity scores or mucosal evaluation), longevity
follow-up (at least 3 months), and bias due to drop-out or
incomplete follow-up. A follow-up of 3 months was chosen
due to case reports that demonstrated improvement after
1 month.152.3. Data analysis
Data from all included publications were extracted into IBM
SPSS Statistics (Version 20.0. Armonk, NY: IBM Corp.).
Descriptive statistics were completed. A clinical remission
rate of all known studies and patients was calculated. To
minimize risk of publication bias, a secondary analysis was
performed using cohort studies only and included only full
publications or abstracts with clearly described selection
and outcome criteria. A meta-analysis was performed with
the pooled estimate proportion of patients that achievedStudies included
analysi
(n = 9)
Articles asse
eligibili
(n = 22
Case studies 
(n = 8) 
5 case series 
3 case reports 
Cohort stu
(n = 9)
Records scr
(n = 81
Records after duplic
(n = 81
Id
en
tif
ic
at
io
n 
El
ig
ib
ili
ty
 
In
cl
ud
ed
 
Sc
re
en
in
g 
Records identified through 
database searching 
(n = 824) 
Studies inclu
quantitative s
(n = 18
Figure 1 Flow-diagramclinical remission. This data was pooled using a random
effects model with the DerSimonian–Laird method calculat-
ed with Meta-Analyst software (version Beta 3.13; Tufts
Medical Center, Boston, MA).16,17 Statistical heterogeneity
was assessed using the Cochran's Q test (χ2) and I2 method. In
the Q test a P value of b0.1 was deemed statistically
significant. The I2 method was used to assess for degree of
heterogeneity, with a score discrimination of 0–40%, 30–
60%, 50–90% and 75–100% consistent with low, moderate,
substantial and considerable heterogeneity, respectively.18
3. Results
3.1. Study characteristics
Eight-hundred-seventeen studies were identified (Fig. 1).
After review of the titles and abstracts, 795 papers were
excluded based on the criteria determined by the PICOS
question. Of those that remained, another 3 studies were
excluded because they included data previously reported in
other publications. One additional study did not provide
clear clinical outcome measures and was subsequently
excluded as well.19 Eighteen studies were included in the
final review. This included 9 prospective uncontrolled cohort in meta-
s 
 
ssed for 
ty 
) 
Articles excluded, with 
partial overlap of data or 
no clear clinical endpoints 
(n = 4)
dies 
 
Records excluded 
(n = 795) 
Studies did not include FMT 
or IBD or had co-infections  
eened 
7) 
ates removed 
7) 
Additional records identified through 
other sources 
(n = 6) 
ded in 
ynthesis  
)
Randomized controlled 
trial 
(n = 1) 
of identified studies.
Table 2-1 Case study characteristics.
Nr Study #IBD
pts
IBD type IBD severity FMT dosage FMT
delivery
Pre-Abs/lavage Frequency Donor Follow-up
1 Bennet et al.
(1989)2
1 UC Severe NR Large
volume
enema's
NR Multiple × 1 NR 6 months
2 Borody et al.
(1989)4
2 UC, CD Active NR NR NR NR NR 1–
12 months
3 Borody et al.
(2001)5
3 UC Quiescent Suspended in 200 ml
saline + table spoon
psyllium
Enema NR Daily × 5 days Healthy
adults
8–
28 months
4 Borody et al.
(2003)7
6 UC Severe 200–300 g (diluted to
200–300 ml)
Enema Vancomycin, metronidazole and
rifampicin for 7–10 days + 3 L oral
PEG solution
Daily × 5 days Family or
close relation
1–
13 years
5 Borody et al.
(2011)6
3 IBD IM/anti-TNF
refractory-severe
NR Enema
(self)
NR Daily &
weekly × 34–70
Clinic donor,
family,
partner
1–4 years
6 Borody et al.
(2011)3
1 UC + ITP Chronic-relapsing
UC
NR NR NR NR NR NR
7 Kao et al.
(2014)9
1 IBD Moderate–severe 400 cm3 fresh fecal
suspension
Colonoscopy NR ×3 (0, 4,
10 weeks)
Universal
donor
2 months
8 Kellermayer
et al. (2013)8
4 (−1 a) UC IM/anti-TNF
dependent
NR Colonoscopy NR
Serial
? N5 months
NR = Not reported.
a Excluded from final analysis due to enema intolerance.
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Table 2-2 Cohort study characteristics.
Nr Study #IBD
pts
IBD
type
IBD severity FMT dosage FMT delivery Pre-Abs/lavage Frequency Donor Follow-up
1 Vermeire et al.
(2012)27
4 CD Medically-refractory 200 g feces NJ infusion NR 3× in 36 h Healthy donor 2 months
2 Kunde et al.
(2013)23
10 (−1 a) UC Mild–moderate 90–113 g/250 ml Enema up to
(4 × 60ml)/day
NR ×5 days Parents 6 weeks
3 Kump et al.
(2013)22
6 UC Therapy-refractory 100–150 g/200–350 ml
saline– N total 300–500 ml
Colonoscopy Lavage of donor
pre collection
×1 Nonrelatives,
different household
1 year
4 Angelberger
et al. (2013)20
5 UC Severe Initially 60 g/250 ml NJ 17–25
g/250 ml. Enema 6–22 g/100 ml
NJ + enema Metronidazole for
5–10 days
×3 consecutive
days
No family/hospital
staff
N1 year
5 Suskind et al.
(2014)25
9 CD Mild–moderate NR NG NR ×1 parent 6 weeks
6 Landy et al.
(2013)24
5 UC Chronic refractory
pouchitis
30 g/250 ml saline Nasogastric NR ×1 Nominated by
participating pts
4 weeks
7 Zhang et al.
(2013).28
16 CD Refractory
(HBI ≥ 8)
NR Gastroscopic NR ×1 NR 1 month
8 Damman et al.
(2014)21
8 (−1 a) UC Mild–moderate
(UCDAI 3–10)
NR Colonoscopic Standard
colonoscopy prep
×1 Chosen by recipient 12 weeks
9 Vaughn et al.
(2014)26
9 CD Active CD (HBI ≥ 6) 50 g in 250 ml saline Colonoscopic Standard
colonoscopy prep
×/>1 Healthy unrelated 12 weeks
NR = not reported; NJ = nasojejunal tube. NG = Nasogastric tube. Abs = antibiotics.
a Excluded from final analysis due to enema intolerance.
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1575Fecal Therapy for Inflammatory Bowel Diseasestudies and 8 retrospective case series and case reports (5 case
series and 3 case reports).2–9,20–28 In addition, one random-
ized controlled trial (RCT) was identified and included in this
review.29. Disease subtypes were distributed as follows among
the publications: 11 UC, 4 CD, 2 ‘IBD unspecified colitis’, and 1
publication included more than one disease subtype. One
systematic review of IBD patients both with and without
co-morbid CDI was found.10 Nometa-analyses were identified.
Tables 2-1 and 2-2 present the characteristics of each original
study.3.2. Risk of bias of individual studies
All cohort studies exhibited ascertainment of FMT exposure,
assessment of outcome and adequacy of follow-up. However,
only 4 studies met the length of follow-up requirements and
documented no prior FMT exposure.21–23,26 With the exception
of two studies, all publications included cohorts with either
severe disease or disease refractory to standard therapy.
Publication dates ranged from 1989 (case studies) to
2014. Over 60% of studies were published in 2013 or 2014.
The earliest two case reports were published in 1989 and the
first abstract of a cohort study in 2012.2,4,27 Each case study
included 1–6 patients. Cohort studies ranged from 4 to 16
patients. The RCT included 31 patients that underwent FMT
and 30 that received placebo treatment.3.3. Patient demographics
Eighteen publications yielded discrete 122 patients (79
ulcerative colitis (UC) (5 of which had a status of
post-colectomy pouchitis), 39 Crohn's disease (CD), and 4
IBD unclassified). Studies included both pediatric and/or
adult patients. The age range of participants extended from
7 years to 64 years. Clinical follow-up of patients ranged
from 1 week to 13 years with a median of 1.5 months.Table 3 Clinical outcomes of cohort studies & protocol type.
No. Study Deterioration No improv
1 Vermeire et al. (2012)27 (n = 4) – 4
2 Kunde et al. (2013)23 (n = 9) 3 a
3 Kump et al. (2013)22 (n = 6) 1 c 3
4 Angelberger et al. (2013)20 (n = 5) 2 e 2
5 Suskind et al. (2014)25 (n = 9) – –
6 Landy et al. (2013)24 (n = 5) NR NR
7 Zhang et al. (2013)28 (n = 16) – 1
8 Damman et al. (2014)21 (n = 7) 1 4
9 Vaughn et al. (2014)26 (n = 9) – 3
CR = Clinical remission; ER/HR = endoscopic or histologic remission; N
Activity Index; MCID = minimal clinically important difference.
a Within PUCAI b 20 MCID.
b Improvement N 20 PUCAI MCID.
c Initial improve then relapse + colectomy.
d Additional reduction of (3 and 4 pts of Mayo score).
e Partial deterioration after 4 weeks w/ returning to baseline.
f Reduction by 4 points on Mayo score.
g Patient was also in clinical remission.3.4. Disease severity and efficacy of FMT
Of the 122 patients included in this review, 3 patients were
excluded from the analysis due to FMT enema intolerance. Of
the remaining 119 patients in the cumulative analysis, 27 (23%)
were described as having mild or mild/moderate disease, 16
(13%) as havingmoderate/severe, and 19 (16%) as having severe
disease. Other disease descriptors included 10 (8%) “therapy
refractory”, 44 (37%) “active disease”, and 5 (4%) “refractory
pouchitis”. Overall, 45% (54/119) of patients achieved clinical
remission during follow-up. Mucosal healing was achieved in 12
of the 16 (75%) case study patients. In cohort studies, mucosal
healing was observed in 1 of 36 (3%) patients and not described
in the remaining patients (n = 34) (Table 3). Four of the 70 (6%)
patients in the cohort studies deteriorated after FMT adminis-
tration. However 2 of these improved and recovered to baseline
by week 8 of follow-up.
Moayyedi et al. completed an RCT that compared FMT of
31 patients receiving fecal enemas to 30 patients receiving
water enemas.29 Patients with active UC (as defined by a
Mayo score of ≥4 and an endoscopic sub score of ≥1)
received FMT or placebo weekly for 6 weeks. At week 7, 7
patients (23%) who received FMT achieved remission (as
defined by a Mayo score b2 and an endoscopic sub-score of
0) compared with 2 patients (7%) who received placebo (P =
0.15). Absolute Mayo scores and health-related quality of
life (HRQoL) (measured by the general EQ-5D or IBD specific
IBDQ) did not significantly vary between groups at 6 weeks.
3.5. Meta-analysis of cohort studies
The cohort studies included in this meta-analysis were
awarded at least a score of 3/6 on the Newcastle–Ottawa
Scale (Table 1). Among the 9 cohort studies included, the
pooled proportion of patients who achieved clinical remis-
sion was 36.2% (95% CI 17.4%–60.4%) (Fig. 2), with a median
effect size of 0.29. This was consistent with moderate
heterogeneity (Cochran's Q, P = 0.011; I2 = 37%). A funnelement Improvement no remission CR ER/HR Protocol type
– – – NR
3 b 3 NR Fresh
2 d – – Frozen
1 f – – Fresh
1 8 NR NR
NR – – Fresh
3 12 NR Fresh
– 2 1 g Fresh
2 4 – Frozen
R = not (exactly) reported; PUCAI = Pediatric Ulcerative Colitis
Figure 2 Forest plot of all cohort studies' overall pooled estimate of clinical remission (CR) of 36.2% (95% CI 17.4%–60.4%).
1576 R.J. Colman, D.T. Rubinplot of the meta-analysis can be found in the supplementary
material (Fig. 4).3.6. Subgroup analyses
Among studies that included UC patients only, the propor-
tion of patients achieving clinical remission was 22% (95% CI
10.4%–40.8%) (Fig. 3a). This was a statistically homogenous
meta-analysis (Cochran's Q, P = 0.37; I2 = 0%). After exclud-
ing a single pouchitis study, the subgroup analysis (which
now comprised almost only left-sided and extensive/
pancolitis patients) demonstrated a pooled estimate of
achieved clinical remission of 24.1% (95% CI 11.1%–44.9%),
with a low risk for heterogeneity (Cochran's Q, P = 0.35; I2 = 0%)
(Fig. 3b). The subgroup analysis for CD consisted of 4 studies and
demonstrated moderate heterogeneity (Cochran's Q, P = 0.05;
I2 = 37%). Due to the relatively larger sample size and
magnitude of response in Zhang's and Suskind's studies, the
pooled estimate for clinical remission was 60.5% (95% CI
28.4%–85.6%) (Fig. 3c).25,28 Funnel plots of the individual
subgroup meta-analyses can be found in the supplementary
material (Fig. 5).3.7. Studies focusing on younger populations
Two studies focused exclusively on young patients (aged 7 to
20 years).23,25 The pooled estimate for clinical remission
among patients included in these studies (1 UC patient and 1
CD patient) was 64.1% (95% CI 10.6%–96.4%, Cochran's Q,
P = 0.029; I2 = 44%) (Fig. 3d) and is consistent with moder-
ate heterogeneity. In line with the results of other studies
that utilized an older patient population, mucosal healing
was not reported.3.8. Donor selection
Donor descriptors were reported in 105 of 122 patients
receiving FMT. Forty-seven of these 105 patients (45%) were
involved in the donor selection process. Twenty-three
patients received their fecal material from a first degree
relative. In 3 of the 5 cohort studies that contained patients
who achieved remission, included donors that were
first-degree relatives.21,23,25,28 One of these 5 studies
(Zhang et al.) did not report any donor source, and the
other study (Vaughn et al.) used healthy anonymous
donors.26,283.9. Preparation
Preparation methods of cohort studies included both fresh
(n = 5) and frozen (n = 2) protocols. Of those studies that
demonstrated clinical remission, 60% (3/5) used a fresh
feces protocol, 20% (1/5) used a frozen protocol, and the
other did not report this.21,23,25,26,283.10. FMT delivery and frequency
FMT delivery methodology included enema administration
(n = 7), nasogastric/nasojejunal (n = 4), colonoscopic instil-
lation (n = 5) and gastroscopic instillation (n = 1). At least
41% (n = 34) of the patients in the case and cohort studies
received FMT more than once (some studies did not
clarify).3,4 In one case study, administration was reported
to be as high as 70 times in a single patient.6 There was no
correlation between efficacy and number of FMT sessions
performed. The majority of the case series reported
multiple FMT sessions. Of the 5 cohort studies that
demonstrated clinical remission, 1 study (Kunde et al.)
Figure 3 Individual forest plots of subgroups: a. Forest plot of UC only. Pooled estimate of CR 22% (95% CI 10.4%–40.8%). b. UC
without pouchitis. Pooled estimate of CR 24.1% (95% CI 11.1%–44.9%). c. CD only pooled estimate of CR 60.5% (95% CI 28.4%–85.6%).
d. Young population (aged 7–20 years) studies only. Pooled estimate of CR 64.1% (95% CI 10.6%–96.4%).
1577Fecal Therapy for Inflammatory Bowel Diseaseadministered enemas for 5 consecutive days while the other
4 studies (Damman et al., Suskind et al., Vaughn et al., and
Zhang et al.) performed either a single nasogastric, single
gastroscopic or colonoscopic administration.21,23,25,26,28 The
RCT conducted weekly single enema administrations for
6 weeks during the blinded phase.293.11. Safety and adverse events
Adverse events were monitored and reported in most cohort
studies (except Damman et al. and Landy et al.) but in none
of the case studies. Overall, FMT was well tolerated. No
serious adverse events were reported by any study. Table 4
provides an overview of all adverse events reported during
FMT follow-up. Other specifications included administration
routes, duration and if medical treatment was required.
Fever in varying degrees, with or without chills, abdominal
tenderness, and CRP elevation after FMT were reported in 11
patients (15%) from 4 studies.20,22,23,27 Fever severity ranged
from self-limiting to requiring acetaminophen treatment
and duration ranged from several hours up to two days afterFMT administration. Almost all other reported events
included the gastrointestinal (GI) tract and were thought to
be directly related to the administration procedure (such as
NJ tube irritation).20 One study reported a patient with
pancreatitis of unknown origin during follow-up.20 In the RCT
no major adverse events were observed although two of the
(UC) patients receiving FMT were diagnosed with Crohn's
disease after receiving FMT and one patient in the placebo
group.293.12. Microbiota and histological analyses
Microbiota analysis was reported in six studies. Four of
these examined FMT efficacy among UC patients and 2
among CD patients. All six studies analyzed the microbiome
of fecal samples but only Kump and colleagues analyzed the
microbiome of mucosal samples.22 In the UC studies,
Angelberger et al. demonstrated that recipient microbiota
acquired, and subsequently maintained, donor microbiota
similarity in 1 of 5 patients for at least 12 weeks.20 Of
interest, change in microbiota occurred in the only patient
1578 R.J. Colman, D.T. Rubinthat had symptomatic response to FMT (after a transient
increase of CRP). Data from Angelberger et al. also suggests
a correlation between Mayo scores and an overrepresenta-
tion of Enterobacteriaceae and an underrepresentation of
Lachnospiraceae at the family level.20 Kump et al. found no
long-term difference in bacterial richness or diversity.
However, an analysis at phylum level demonstrated a
significant reduction seen in Proteobacteria and an increase
in Bacteroidetes after FMT.22 Colonic microbiota of recip-
ients became more similar to the donor microbiota in 50% (3
of 6) of patients. These changes were not associated with
clinical response.22 Two other UC studies also included
metagenomic analyses.21,30 Damman et al. found a positive
correlation of FMT, including Gordonibacter pamelaea and
improved UCDAI scores.21 The group that conducted
the RCT found an increase in butyrate producing groups in
responders versus non-responders.30 These groups included
Ruminococcus, Blautia and Lachnospiraceae (Roseburia and
Faecalibacterium). In addition, the microbiome diversity was
not altered post-FMT in either the responders or the
non-responders. However, feces of responders demonstrated
several functional metagenomic differences including butanoate
metabolism, biosynthesis, and degradation of secondary metab-
olites and bacterial toxins compared to non-responders.
Vermeire et al. analyzed both donor and recipient stool
pre-FMT administration among patients with Crohn's dis-
ease.27 Results suggested that microbiota of donor stool
appeared clustered on a phylogenetic level. In contrast,
recipients' stool did not reveal coherent clustering and
returned to their baseline composition at week 8. When
Vaughn et al. investigated the microbiome by 16S rRNA
sequencing as well as deep shotgun metagenomic sequenc-
ing, they found that the microbiome had shifted towards less
disease associated (donor) taxa.26 In addition, deep shotgun
metagenomics of one donor–recipient pair found that only
10% of recipient organisms of the pre-FMT analysis were left.
Cellular changes from mucosal biopsies were examined in
only one study.24 Landy et al. monitored tight junction
alteration and immunological parameters pre-FMT and
4 weeks post-FMT in 5 patients with pouchitis. None of
these parameters changed post-FMT and no patients within
this study demonstrated improvement.4. Discussion
To date, this is the largest systematic review and first
meta-analysis of FMT in IBD. The results of these analyses
reveal additional insights into the promise and limitations of
this novel therapy. We identified 18 (1 RCT, 9 cohort studies
and 8 case studies) studies that examined FMT as primary or
adjunctive therapy for IBD. Clinical remission was achieved
in 54 of 119 (45%) of patients. Notably, the inclusion of case
studies in this analysis elevates the risk of publication bias. A
meta-analysis of cohort studies was performed to minimize
this bias, and demonstrated a pooled estimate for achieving
short-term clinical remission after FMT of 36.2%. A subgroup
meta-analysis including only UC patients of cohort studies
showed a pooled estimate for achieving remission of 22%.
This rate appears similar to the remission rate suggested by
the RCT by Moayyedi et al. among UC patients, approx-
imately 23%. In examining subgroup meta-analyses alone, itmight appear that FMT is more efficacious in a younger
population. However, the results are significantly heteroge-
neous, which considerably limits the applicability of the
conclusions. In addition, factors such as duration of disease
or differences in environmental triggers cannot be ade-
quately accounted for with a sample size this small. A limited
number of cohort studies described and/or observedmucosal
healing, an endpoint that would have increased the
objectivity of the authors' findings. These findings are
corroborated by Moayyedi et al., who demonstrated no
difference between the two groups when the endoscopic
Mayo score or HRQoL scores were used as endpoints.29 While
it would be of great interest to further analyze factors such
as disease severity and location or extent of disease, the
total number of patients used to calculate the rate of
patients achieving clinical remission was too small to draw
statistically meaningful conclusions.
This review has several methodological and theoretical
limitations. First, the applicability of the results from this
review and meta-analysis is constrained by the lack of
published research and the methodological quality of
research that has been published so far. All eligible studies
were included in the initial pooled analysis systematic
review. While this increases the risk for heterogeneity and
biases, these studies were included to provide a general
updated overview of data available and to provide compar-
ison with the 2 previously published systematic reviews. To
minimize these risks, an additional meta-analysis was
performed and only included cohort studies. Additionally,
meta-analysis and subgroup meta-analyses were completed
to further address concern for bias. These analyses attempt
to control for study variation and limit the undue influence
of cohort studies, the heterogeneity of study populations,
and FMT methodology (e.g. administration type and fre-
quency). The limited research within this field precluded the
analysis of specific FMT delivery protocols. As such, the
variability in methodology may have diluted the effect or
efficacy of a particular treatment paradigm. It is also
possible that the inclusion of case studies within this review
inadvertently inflated the reported effect size and cumula-
tive results.
There are 2 published systematic reviews of FMT among
IBD patients that were completed prior to this publica-
tion.10,11 While results from the systematic review by
Anderson and colleagues demonstrated endoscopic and
histologic disease remission in 15 of 24 patients (63%) 10,
the validity of the data was limited by significant method-
ological concerns. The authors did not include a complete
clinical overview of patients achieving clinical remission.
Therefore, the high rates of remission in that review can
likely be attributed to publication bias; at that time, there
were only 2 cohort studies in press, both of which did not
report or demonstrate any endoscopic or histologic remis-
sion. In addition, the authors designated ‘symptom-free’ as
a categorical endpoint but included no pre-defined criteria.
A second systematic review by Sha and colleagues included
outcomes of FMT for IBD treatment and was published in the
same journal. The review contained mostly case reports and
calculated a ‘success rate’ of 77.8% for adult IBD patients.11
However, this review also contained several methodological
limitations, most notably that FMT outcomes were measured
by treatment ‘success rates’ and not any other more
Table 4 Adverse events reported during FMT & follow-up (n = 7/9 cohort studies).
FMT administration Adverse events per patient Time span & action
Vermeire et al.
(2012)27
Single NJ tube • 3/4 patients high fever and abdominal ten-
derness (n = 3)
• Start at day of FMT and disap-
peared after 2 days
Kunde et al.
(2013)23
Daily enemas ×5 consec
days
• Moderate fever & chills 3 h after FMT
(n = 1)
• Single episode low grade fever
no Rx necessary (n = 1)
• Other GI symptoms (n = 9)
• Fatigue (n = 3)
• All self-limiting except 1 fever.
• (n = 1) Required acetamino-
phen
and diphenhydramine.
Kump et al.
(2013)22
Single colonoscopy Self-limiting fever + incr stool frequency
(+CRP, and IL-6 elevation) (n = 1)
Day 1 post-FMT–day 3
(self-limiting).
Angelberger et
al. (2013)20
NJ + enema (both on 3
consec days)
• Fever + CRP elevation (n = 5)
• NJ tube irritation (n = 5)
• Flatulence (n = 2)
• Vomiting (n = 1)
After fever in subject 1, all
patients received
metronidazole
pre-FMT and some received
probiotics.
Suskind et al.
(2014)25
Single NG Mild gassiness and bloating (n = 3) Day after FMT no intervention.
Zhang et al.
(2013)28
Single gastroscopic Increased diarrhea (n = 5) Onset within 3 h (self-limiting)
Vaughn et al.
(2014)26
Single colonoscopic No immediate complications or adverse events in the first 4 weeks post-FMT.
NJ = Nasojejunal tube. NG = nasogastric tube.
1579Fecal Therapy for Inflammatory Bowel Diseasevalidated measures. In addition, one of the studies that were
included in the overall success rate was a case report that
did not assess clinical outcome, but investigated microbiota
modification only.31 Two other studies that are included in
this review appear to overlap with earlier studies published
by the same group, and one of these included C. difficile
eradication in its success rate.32,33
The etiology of IBD is complex, multifactorial and
incompletely understood. Throughout the past century
many theories have proposed and/or implicated the role of
different bacteria.34 In particular, microbial dysbiosis has
been hypothesized as a key player in disease development.35
Studies that have examined the role of altered microbiota in
IBD demonstrate reduced gut microbiome richness and
biodiversity, such as a decrease in Feacalibacteria with
Feacalibacterium prausnitzii in mucosa-associated microbi-
ota or feces.36,37 In contrast to what might be then expected,
probiotics have demonstrated mixed results as treatment for
ulcerative colitis.38–40 A definite causal relationship be-
tween bacteria and the pathogenesis of IBD has not yet been
identified. As a result, proof of Koch's postulates for IBD is
elusive and it remains possible that all observations about
the microbiome and attempts to modify it are simple
associations rather than causal relationships.41,42
A strength of our review is that it provides a comprehen-
sive overview and that it excluded studies that included
co-morbid IBD and GI infections. FMT has strong empirical
support for CDI. As such, symptomatic improvement of
symptoms after transplantation in an individual with
co-morbid diagnosis cannot be attributed to improvement
in IBD directly. In addition, this is the first systematic review
to include a complete meta-analysis of cohort studies alone.
As meta-analyses allow for a more objective evaluation of
FMT efficacy in IBD patients, its inclusion within the greatersystematic review provides a more comprehensive view of
treatment success.4.1. Safety
Results from these analyses suggest that FMT is generally
tolerable and safe. Although multiple studies report fever
(predominantly self-limiting) post-FMT, most conceptualize
post-administration symptoms as a consequence of the
administration procedures themselves. Long-term immuno-
logic effects or onset of latent infections cannot be assessed
in these studies due to relatively short follow-up. Thus,
rigorous screening of the donor and donor stool remains
particularly important. To this end, both the infectious and
gastroenterological societies recommend the utilization of
the patient's partner, family or family friend for feces
donation.43 Given the heritability of both IBD and the gut
microbiome itself, the role of donor selection should be
investigated further.
Due to the emerging nature of FMT in IBD, this review is
limited both by the quality and number of studies and
published RCTs available (although we did include the one
RCT of FMT in IBD that is currently available). As a result,
our meta-analysis of cohort studies had small subgroup
analyses with a heterogeneous population among most
subgroups. Due to the experimental nature of this therapy
and myriad of variables in study design (such as donor
choice, preparation of feces and substance delivery) it is not
possible to compare all of these individual factors yet. Two
recent systematic reviews of FMT in patients with CDI (one
of which included a meta-analysis) did not find significant
differences in clinical outcomes for studies that differed in
donor selection or FMT delivery.44,45 This said, as IBD is a
1580 R.J. Colman, D.T. Rubinmore complicated and heterogeneous pathology than CDI,
it may be likely that these results will vary among the IBD
patient population. Other factors may have influenced
these outcomes, including: differences in preparation of
recipients and donor stool, administration of antibiotics to
the recipient pre-FMT, and lavage of the donor before feces
collection.20,22 In addition, follow-up varied as well
and protocols differed in both duration and methods.
Mucosal assessment was not always performed prior to
FMT administration and, as a result, clinical information
about disease severity and location was not consistently
documented.
In these, the early days of attempting microbiota
modification as treatment for IBD, it is important to
recognize the strengths and range of documented research
while being mindful of its limitations and the pressing need
for ongoing, thoughtful study. More research from random-
ized controlled trials that evaluate endoscopic appearance
pre-FMT and mucosal healing post-FMT and that allow for
sufficient follow-up clearly is needed. The approach to FMT
in IBD is in its infancy, and much work remains in order to
clarify its ultimate utility. Future work must assess the role
of the different FMT delivery modalities and frequencies,
and continue to assess the microbiome in both recipient and
donor, with the ultimate goal of refining today's crude
attempts in favor of more directed approaches based on
specific organisms and classes of organisms. In addition, the
timing of fecal microbiota manipulation should be further
explored, perhaps to occur in maintenance phase after
successful immune-suppression-based induction, or in com-
bination with immune modifying strategies.4.2. Conclusions
The approach to FMT in IBD is in its infancy, and much work
remains in order to clarify its ultimate utility. Future work
must assess the role of the different FMT delivery modalities
and frequencies, and continue to assess the microbiome in
both recipient and donor, with the ultimate goal of refining
today's crude attempts in favor of more directed approaches
based on specific organisms and classes of organisms. In
addition, the timing of fecal microbiota manipulation should
be further explored, perhaps to occur in maintenance phase
after successful immune-suppression-based induction, or in
combination with immune modifying strategies.Conflict of interest
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